Using current techniques, Alzheimer’s disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain. At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer’s take place on the protein level up to 20 years sooner. A two-tier method developed at Ruhr-Universität Bochum (RUB) can help detect the disease at a much earlier stage. The researchers from Bochum published their report in the March 2019 edition of the journal “Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring”.
“This has paved the way for early-stage therapy approaches, where the as yet inefficient drugs on which we had pinned our hopes may prove effective,” says Professor Klaus Gerwert from the Department of Biophysics at RUB.
Protein folds incorrectly
In Alzheimer’s patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur. A team of researchers headed by Klaus Gerwert successfully diagnosed this misfolding using a simple blood test; as a result, the disease can be detected approximately eight years before the first clinical symptoms occur. The test wasn’t suitable for clinical applications however: it did detect 71 per cent of Alzheimer’s cases in symptomless stages, but at the same time provided false positive diagnoses for nine per cent of the study participants. In order to increase the number of correctly identified Alzheimer’s cases and to reduce the number of false positive diagnoses, the researchers poured a lot of time and effort into optimising the test.
As a result, they have now introduced the two-tier diagnostic method. To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer’s diagnosis was positive in the first step. If both biomarkers show a positive result, there is a high likelihood of Alzheimer’s disease. “Through the combination of both analyses, 87 of 100 Alzheimer’s patients were correctly identified in our study,” summarises Klaus Gerwert. “And we reduced the number of false positive diagnoses in healthy subjects to 3 of 100. The second analysis is carried out in cerebrospinal fluid that is extracted from the spinal cord.
“Now, new clinical studies with test participants in very early stages of the disease can be launched,” points out Gerwert. He is hoping that the existing therapeutic antibodies will still have an effect. “Recently, two major promising studies have failed, especially Crenezumab and Aducanumab – not least because it had probably already been too late by the time therapy was taken up. The new test opens up a new therapy window.”
“Once amyloid plaques have formed, it seems that the disease can no longer be treated,” says Dr. Andreas Nabers, head of the research group and co-developer of the Alzheimer’s sensor. “If our attempts to arrest the progression of Alzheimer’s fail, it will put a lot of strain on our society.”
Sensor test is simple and robust
The blood test has been upgraded to a fully automated process at the RUB Department of Biophysics. “The sensor is easy to use, robust when it comes to fluctuation in concentration of biomarkers, and standardised,” explains Andreas Nabers. “We are now conducting in-depth research to detect the second biomarker, namely tau protein, in the blood, in order to supply a solely blood-based test in future,” concludes Klaus Gerwert.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimer's Association to host virtual forumon April 19, 2021 at 5:00 pm
The Alzheimer's Association will host a free virtual forum for Frederick and Washington county residents on Thursday from 1-2:30 p.m.
- Families Of Alzheimer’s, Dementia Patients Relieved Doors Finally Reopen At Long Island Care Facilityon April 19, 2021 at 3:50 pm
Doors finally reopened at Long Island Alzheimer's and Dementia Center and Gladys Hampson of East Meadow was relieved her husband, Bob, can once again attend classes and counseling.
- Doors Finally Reopen At Long Island Alzheimer's And Dementia Centeron April 19, 2021 at 3:28 pm
The pandemic presents special struggles for Alzheimer's and dementia patients. Already isolated at home, many family members have had no breaks in the 24-hour care of their loved ones... until today.
- The Battle Over an Alzheimer’s Treatmenton April 19, 2021 at 3:06 pm
Biogen’s promising drug is caught in the FDA’s political and bureaucratic limbo.
- David Prowse's collection of Star Wars memorabilia to be auctioned for Alzheimer’s Research UKon April 19, 2021 at 1:00 pm
Darth Vader actor David Prowse’s private collection of ‘Star Wars’ memorabilia is set to be auctioned off to benefit Alzheimer’s Research UK.
- Artificial intelligence looks for a 'language' of cancer and Alzheimer'son April 19, 2021 at 11:46 am
Artificial intelligence technology can analyze large amounts of data and look for patterns. Scientists are using machine learning, a type of artificial intelligence, to look for a ‘language’ for ...
- Researchers identify 'instigator' gene associated with Alzheimer's diseaseon April 19, 2021 at 9:06 am
In a new paper published in Nature Communications, Mayo Clinic researchers and collaborators report the protein-coding gene SERPINA5 may worsen tau protein tangles, which are characteristic of ...
- Researchers investigate inhibitory mechanism in Alzheimer's diseaseon April 19, 2021 at 8:57 am
Alzheimer's disease (AD) is a form of progressive dementia interfering with daily living. It is caused by the decline in the number of brain cells resulting in the deterioration of our mental ...
- The Importance of Friendship for Alzheimer’s Patientson April 19, 2021 at 7:30 am
We have gone on this journey together.’ Friends who have been close for years find ways to continue the bond in a new and difficult chapter.
- Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer’s diseaseon April 19, 2021 at 3:46 am
Alzheimer’s disease (AD) is typically associated with hippocampal and cortical pathology, although hippocampal sparing and limbic predominant forms exist. The authors use transcriptomic analysis and ...
via Bing News